GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » CareDx Inc (NAS:CDNA) » Definitions » Beneish M-Score

CareDx (CareDx) Beneish M-Score

: -3.45 (As of Today)
View and export this data going back to 2014. Start your Free Trial

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.45 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for CareDx's Beneish M-Score or its related term are showing as below:

CDNA' s Beneish M-Score Range Over the Past 10 Years
Min: -3.45   Med: -2.65   Max: 5.97
Current: -3.45

During the past 12 years, the highest Beneish M-Score of CareDx was 5.97. The lowest was -3.45. And the median was -2.65.


CareDx Beneish M-Score Historical Data

The historical data trend for CareDx's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CareDx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.14 -2.86 -1.89 -2.88 -3.45

CareDx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.88 -3.30 -3.49 -3.54 -3.45

Competitive Comparison

For the Diagnostics & Research subindustry, CareDx's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CareDx Beneish M-Score Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, CareDx's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where CareDx's Beneish M-Score falls into.



CareDx Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of CareDx for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8839+0.528 * 1.0238+0.404 * 1.205+0.892 * 0.8711+0.115 * 0.7956
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1759+4.679 * -0.159865-0.327 * 1.1309
=-3.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $51.1 Mil.
Revenue was 65.569 + 67.192 + 70.301 + 77.262 = $280.3 Mil.
Gross Profit was 39.956 + 42.659 + 44.414 + 51.296 = $178.3 Mil.
Total Current Assets was $313.7 Mil.
Total Assets was $466.8 Mil.
Property, Plant and Equipment(Net PPE) was $65.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $19.8 Mil.
Selling, General, & Admin. Expense(SGA) was $201.2 Mil.
Total Current Liabilities was $78.1 Mil.
Long-Term Debt & Capital Lease Obligation was $28.3 Mil.
Net Income was -118.097 + -23.485 + -24.953 + -23.749 = $-190.3 Mil.
Non Operating Income was -96.231 + 2.047 + -1.116 + -1.967 = $-97.3 Mil.
Cash Flow from Operations was -8.381 + -10.179 + -0.499 + 0.671 = $-18.4 Mil.
Total Receivables was $66.3 Mil.
Revenue was 82.384 + 79.359 + 80.634 + 79.416 = $321.8 Mil.
Gross Profit was 52.894 + 51.058 + 53.095 + 52.534 = $209.6 Mil.
Total Current Assets was $387.8 Mil.
Total Assets was $543.0 Mil.
Property, Plant and Equipment(Net PPE) was $70.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $16.0 Mil.
Selling, General, & Admin. Expense(SGA) was $196.4 Mil.
Total Current Liabilities was $76.0 Mil.
Long-Term Debt & Capital Lease Obligation was $33.4 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(51.061 / 280.324) / (66.312 / 321.793)
=0.18215 / 0.20607
=0.8839

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(209.581 / 321.793) / (178.325 / 280.324)
=0.651291 / 0.636139
=1.0238

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (313.713 + 65.137) / 466.826) / (1 - (387.849 + 70.218) / 542.991)
=0.188456 / 0.1564
=1.205

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=280.324 / 321.793
=0.8711

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(16.007 / (16.007 + 70.218)) / (19.824 / (19.824 + 65.137))
=0.185642 / 0.233331
=0.7956

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(201.202 / 280.324) / (196.424 / 321.793)
=0.717748 / 0.610405
=1.1759

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((28.278 + 78.072) / 466.826) / ((33.406 + 75.975) / 542.991)
=0.227815 / 0.201442
=1.1309

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-190.284 - -97.267 - -18.388) / 466.826
=-0.159865

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

CareDx has a M-score of -3.45 suggests that the company is unlikely to be a manipulator.


CareDx (CareDx) Business Description

Traded in Other Exchanges
Address
8000 Marina Boulevard, Brisbane, CA, USA, 94005
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its primary operations are in Brisbane, California; Omaha, Nebraska; Fremantle, Australia and Stockholm, Sweden.
Executives
Reginald Seeto officer: See Remarks C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
Peter Maag director, officer: President and CEO CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Abraham Ronai officer: See Remarks C/O CAREDX, INC., 8000 MARINA BLVD, BRISBANE CA 94005
Grace Colon director C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Abhishek Jain officer: See Remarks C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Michael Goldberg director 3000 SAND HILL ROAD, BUILDING 3, SUITE 290, MENLO PARK CA 94025
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Ankur Dhingra officer: Chief Financial Officer C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080
Arthur A Torres director 87 BVENA VISTA TERRACE, SAN FRANCISCO CA 94117
Alexander L Johnson officer: Chief Business Officer C/O DIADEXUS, INC., 349 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Hannah Valantine director 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Sasha King officer: Chief Commercial Officer C/O CAREDX, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
William A Hagstrom director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Ralph Snyderman director C/O SAIC, 10260 CAMPUS POINT DR M/S F3, SAN DIEGO CA 92121
Marcel Konrad officer: See Remarks C/O CAREDX, INC., 1 TOWER PLACE, 9TH FLOOR, SOUTH SAN FRANCISCO CA 94080